STOCK TITAN

Cyclerion Therapeutics Inc - CYCN STOCK NEWS

Welcome to our dedicated news page for Cyclerion Therapeutics (Ticker: CYCN), a resource for investors and traders seeking the latest updates and insights on Cyclerion Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cyclerion Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cyclerion Therapeutics's position in the market.

Rhea-AI Summary
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) appoints Regina Graul, Ph.D., as president, leading the organization to develop treatments for serious diseases. Peter Hecht, Ph.D., steps down as CEO but continues as a strategic consultant and board member.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.73%
Tags
management
-
Rhea-AI Summary
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) announces the appointment of Dina Katabi, Ph.D., and Michael Higgins to its Board of Directors. Dr. Katabi is a world leader in healthcare AI applications at MIT and inventor of wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders. Mr. Higgins is a seasoned biopharma executive with extensive board experience and a track record of launching successful companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.08%
Tags
management
-
Rhea-AI Summary
Cyclerion Therapeutics and Tisento Therapeutics have closed their asset purchase agreement, with Tisento receiving equity ownership in Cyclerion and an upfront cash payment. Tisento will use the funding to develop zagociguat, a potential treatment for MELAS and other mitochondrial diseases. Phase 2a clinical data showed positive results for zagociguat in patients with MELAS. Cyclerion shareholders will benefit from future Tisento value creation without further financial obligations. Cyclerion also received a $10.4 million cash payment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.14%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.35%
Tags
none
-
Rhea-AI Summary
Cyclerion Therapeutics announces corporate updates and Q1 2023 financial results, including a definitive agreement to sell assets to a new company formed by shareholders and new investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.57%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.54%
Tags
Cyclerion Therapeutics Inc

Nasdaq:CYCN

CYCN Rankings

CYCN Stock Data

9.13M
1.13M
20.77%
41.34%
0.81%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About CYCN

cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.